ID   PER-145
AC   CVCL_W976
DR   Wikidata; Q54947175
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2720661;
RX   PubMed=3472651;
RX   PubMed=7540895;
RX   PubMed=7541097;
RX   PubMed=12883040;
RX   PubMed=17117183;
CC   Doubling time: 108 hours (PubMed=17117183).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=17117183
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 8,9
ST   D16S539: 12,13
ST   D18S51: 14,16
ST   D19S433: 16
ST   D21S11: 30,33.2
ST   D2S1338: 16,19
ST   D3S1358: 18
ST   D5S818: 10,11
ST   D7S820: 10,12
ST   D8S1179: 9,11
ST   FGA: 19,20
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_W977 ! PER-163
OI   CVCL_W978 ! PER-164
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 10-04-25; Version: 10
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=2720661;
RA   Kees U.R., Ford J., Dawson V.M., Piall E.M., Aherne G.W.;
RT   "Development of resistance to 1-beta-D-arabinofuranosylcytosine after
RT   high-dose treatment in childhood lymphoblastic leukemia: analysis of
RT   resistance mechanism in established cell lines.";
RL   Cancer Res. 49:3015-3019(1989).
//
RX   PubMed=3472651;
RA   Kees U.R.;
RT   "Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose
RT   treatment childhood lymphoblastic leukemia: isolation of a drug
RT   resistant and a sensitive cell line.";
RL   Cancer Res. 47:3088-3091(1987).
//
RX   PubMed=7540895; DOI=10.1097/00001813-199504000-00015;
RA   Kees U.R., Avramis V.I.;
RT   "Biochemical pharmacology and DNA methylation studies of arabinosyl
RT   5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia
RT   cell lines PER-145 and PER-163.";
RL   Anticancer Drugs 6:303-310(1995).
//
RX   PubMed=7541097;
RA   Kees U.R., Ashman L.K.;
RT   "Synergistic action of interleukin-2 and Steel factor (SLF) on a human
RT   T lymphoblastoid cell line.";
RL   Leukemia 9:1046-1050(1995).
//
RX   PubMed=12883040;
RA   Kees U.R., Ford J., Watson M., Murch A.R., Ringner M., Walker R.L.,
RA   Meltzer P.S.;
RT   "Gene expression profiles in a panel of childhood leukemia cell lines
RT   mirror critical features of the disease.";
RL   Mol. Cancer Ther. 2:671-677(2003).
//
RX   PubMed=17117183; DOI=10.1038/sj.bjc.6603447; PMCID=PMC2360743;
RA   Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J.,
RA   Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.;
RT   "Authenticity and drug resistance in a panel of acute lymphoblastic
RT   leukaemia cell lines.";
RL   Br. J. Cancer 95:1537-1544(2006).
//